The scale of the potential problem is considerable. When the researchers pooled studies that used consistent diagnostic thresholds for vitamin B12 deficiency, they found that approximately 32.1 percent of metformin-treated patients were deficient — nearly one in three. That figure, derived with strikingly low statistical heterogeneity (an I² of 0.0 percent, meaning the included studies agreed with each other to an unusual degree), suggests the association is not an artifact of any single population or laboratory method. In a drug taken by well over one hundred million people worldwide, a deficiency prevalence of one third translates into an enormous population-level burden.

The link between metformin and nerve damage held up across study designs. In the pooled analysis of six cross-sectional studies, metformin users had 84 percent higher odds of peripheral neuropathy than non-users (pooled odds ratio of 1.84, with a 95 percent confidence interval of 1.18 to 2.88, and a p-value of 0.007). Two cohort studies pointed in the same direction: one reported an adjusted odds ratio of 1.57, while another found a hazard ratio of 1.84, meaning that over time, metformin users developed neuropathy at nearly twice the rate of comparable patients not taking the drug. Consistency across cross-sectional snapshots and longitudinal follow-up strengthens the case that the association is not merely a statistical fluke.

The mechanistic story centers on vitamin B12, or cobalamin, an essential micronutrient the human body cannot synthesize. B12 is a cofactor for two enzymatic reactions: one converts methylmalonic acid to succinyl-CoA, and the other regenerates methionine from homocysteine via methylation. When B12 runs short, methylmalonic acid accumulates and impairs myelin synthesis and maintenance — the fatty sheath that insulates nerve fibers and allows electrical signals to propagate rapidly. The resulting damage manifests as the numbness, tingling, burning pain, and balance problems characteristic of peripheral neuropathy. Metformin is thought to interfere with B12 absorption in the ileum, likely through effects on calcium-dependent membrane processes and alterations in intestinal motility and the gut microbiome, though the precise molecular pathway remains an active area of investigation.

Crucially, the meta-analysis showed that B12 deficiency itself is an independent predictor of neuropathy in people with type 2 diabetes. In a diabetes-specific pooling of four studies, B12 deficiency more than doubled the odds of peripheral neuropathy (odds ratio of 2.09, 95 percent confidence interval 1.03 to 4.22, p = 0.041). This is an important distinction, because diabetic peripheral neuropathy is usually attributed to chronic hyperglycemia, oxidative stress, and microvascular disease. The new data indicate that a correctable nutritional deficit contributes a measurable share of the risk — a share that has historically been misattributed to diabetes itself and therefore left untreated.

Perhaps the most striking finding is the evidence of synergy. In one included cohort study, patients who took metformin and were simultaneously B12 deficient faced a hazard ratio of 5.76 for peripheral neuropathy — a nearly six-fold elevation in risk compared with patients who had neither exposure. That multiplicative pattern is biologically plausible: metformin depletes the nutrient, the nutrient’s absence damages myelin, and diabetes independently stresses the same peripheral nerves. When all three forces converge, the nerve’s reserve capacity is overwhelmed. For clinicians, the implication is that the two risk factors cannot be evaluated in isolation; a metformin user with borderline B12 levels may be in a far more dangerous position than either number alone suggests.

The rigor of the review lends weight to its conclusions. The protocol was prospectively registered in PROSPERO before the literature search began, a safeguard against outcome switching and selective reporting. The authors searched PubMed, Google Scholar, Europe PMC, and the Cochrane Central Register from January 2009 to April 2026, and two reviewers independently screened records with strong agreement (Cohen’s kappa of 0.82, well above the conventional threshold for substantial agreement). Study quality was assessed with the Newcastle-Ottawa Scale, and the certainty of evidence was graded using the GRADE framework. The meta-analyses employed random-effects models using the DerSimonian–Laird estimator, the standard approach when true effect sizes may vary across populations.

There are, inevitably, caveats. The headline neuropathy estimate came from cross-sectional pooling with moderate heterogeneity (I² of 68.9 percent), which means the included studies varied considerably in their populations, neuropathy diagnostic tools, and definitions of B12 deficiency. Cross-sectional designs cannot establish temporality — it is possible, though biologically less likely, that patients with neuropathy were simply more likely to be prescribed metformin. The observational nature of the evidence means that randomized trials of B12 supplementation in metformin users remain the gold standard for proving that treatment can prevent or reverse the nerve damage. The authors themselves frame their findings as a call for routine monitoring rather than a verdict against the drug.

Indeed, the clinical calculus is not a simple one. Metformin is among the most effective, best tolerated, and most affordable glucose-lowering agents available, with established cardiovascular benefits and a safety record spanning decades. The researchers are emphatic that the answer is not to abandon the drug but to close the surveillance gap around it. Current practice varies widely: some guidelines recommend periodic B12 testing in long-term metformin users, while others are silent on the matter, and in routine care, B12 levels are often checked only after symptoms appear — by which point neurological damage may be partially irreversible. The finding that deficiency affects roughly a third of treated patients at uniform diagnostic thresholds argues for proactive screening, particularly for those on higher doses or longer durations of therapy.

The practical response, the authors argue, is straightforward: routine B12 monitoring and supplementation for long-term metformin users. Oral B12 supplements are inexpensive, safe, and effective in most cases, and early correction of deficiency offers the best chance of preventing permanent nerve injury. With type 2 diabetes affecting more than half a billion people globally and metformin remaining the first-line therapy almost everywhere, even modest reductions in neuropathy risk through a simple blood test and a cheap vitamin could avert enormous suffering. The study, registered prospectively under PROSPERO number CRD420261363992, transforms a long-suspected side effect into a quantified, actionable clinical target — and reminds the medical world that even the most trusted drugs deserve continued scrutiny.

Subject of Research: Association of long-term metformin use with vitamin B12 deficiency and peripheral neuropathy in type 2 diabetes

Article Title: Association of metformin use with vitamin B12 deficiency and peripheral neuropathy in type 2 diabetes mellitus: a systematic review and meta-analysis

Article References: Mohammed, N., Taha, A. S. O., MohamedSalih, N., Mohammed, M., Rahama, T., Abdelrahman, N., Idris, M. O. A., Saeed, N., & Mustafa, N. A. A. (2026). Association of metformin use with vitamin B12 deficiency and peripheral neuropathy in type 2 diabetes mellitus: a systematic review and meta-analysis. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02520-7

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02520-7

Keywords: metformin, vitamin B12 deficiency, peripheral neuropathy, type 2 diabetes, meta-analysis, systematic review, diabetic neuropathy, cobalamin, drug safety, B12 monitoring, endocrinology, myelin